title: Therapeutic receptor targets of ischemic preconditioning.
abstract: This review focuses on target receptors that have been shown to have the potential to mimic the cardioprotective effect of ischemic preconditioning (IPC). There is an abundance of information concerning the intracellular mechanisms and membrane-bound receptors responsible for IPC. Important intracellular mediators of this cardioprotection likely reside in the activation of multiple kinase cascades. The major players in IPC are thought to include protein kinase C, tyrosine kinases, and members of the mitogen-activated protein kinase signaling family and these topics will be covered in more detail in other papers of this focused issue. However, many of these kinase-mediated mechanisms are triggered by the activation of transmembrane spanning receptors, some of which may be manipulated therapeutically to induce cardioprotection in humans with unstable angina or who are at risk for myocardial infarction. In this review, we will discuss the evidence supporting the possibility of manipulating several of these G protein-coupled receptors as potential therapeutic targets. Stimulation of numerous receptors has been targeted as possible triggers for IPC. Some of those that have been identified include A(1) adenosine, alpha(1) adrenergic, M(2) muscarinic, B(2) bradykinin, delta(1) opioid, AT(1) angiotensin, and endothelin-1 receptors. In general, these receptors are thought to couple to inhibitory G proteins. In this review, we will focus on the most likely therapeutic candidates for cardioprotection, namely adenosine, opioid, and bradykinin receptors since selective agonists and antagonists, either alone or in combination, have most often been shown to mimic or block IPC in numerous animal models and man, respectively. This is not meant to completely rule out other receptors since it is clear that IPC is a phenomenon with multiple pathways that appear to be responsible for the cardioprotection observed.
authors.affiliation: Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee 53226, USA.
authors.forename: Ryan M
authors.initials: RM
authors.lastname: Fryer
authors.forename: John A
authors.initials: JA
authors.lastname: Auchampach
authors.forename: Garrett J
authors.initials: GJ
authors.lastname: Gross
mesh_terms: D000241:Adenosine / Q000378:metabolism; D000818:Animals; D001920:Bradykinin / Q000378:metabolism; D065168:Bradykinin Receptor Antagonists; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism; D009292:Narcotic Antagonists; D009294:Narcotics / Q000378:metabolism; D058915:Purinergic P1 Receptor Antagonists; D018002:Receptors, Bradykinin / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000378:metabolism
chemical_list: D065168:Bradykinin Receptor Antagonists; D009292:Narcotic Antagonists; D009294:Narcotics; D058915:Purinergic P1 Receptor Antagonists; D018002:Receptors, Bradykinin; D011957:Receptors, Opioid; D018047:Receptors, Purinergic P1; D000241:Adenosine; D001920:Bradykinin